(R)-1-(4-ethylphenyl)ethylamine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (R)-1-(4-ethylphenyl)ethylamine
• 英文别名: (1R)-1-(4-ethylphenyl)ethanamine
• 化学式: C₁₀H₁₅N
• mdl: MFCD06761885
• 分子量: 149.236
• InChiKey: AMXXYSXDJUIPMZ-MRVPVSSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  对乙基苯乙酮 在 aluminum (III) chloride 、 (R,R)-(-)-2,3-bis(tert-butylmethylphosphino)quinoxaline 、 氢气 、 苯甲醚 、 zinc(II) chloride 作用下， 以 四氢呋喃 、 二氯甲烷 、 2,2,2-三氟乙醇 为溶剂， 40.0~80.0 ℃ 、100.0 kPa 条件下， 反应 71.0h， 生成 (R)-1-(4-ethylphenyl)ethylamine
  参考文献：
  名称：

  一种合成手性胺化合物的方法

  摘要：

  本发明提供了一种合成手性胺化合物的方法，所述方法包括以下步骤：(1)将式I所示化合物与叔丁基磺酰胺在催化剂存在下反应得到具有式II结构的化合物；(2)将式II所示化合物在铱催化剂和配体存在的条件下，在氢气氛围中进行反应得到式III所示化合物；(3)将式III所示化合物脱去叔丁磺酰基反应得到手性胺化合物；本发明提供的方法，通过酮羰基构建磺酰胺的结构，然后通过磺酰胺结构的不对称催化氢化反应，高效合成了芳烷基胺结构的手性胺化合物，ee值一般在80％以上，最高的ee值达到了99％以上，每一步反应的收率均可达到90％以上，总收率较高。

  公开号：

  CN110092725B

文献信息

• Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors
  申请人：Allen George David

  公开号：US20070111995A1

  公开（公告）日：2007-05-17

  The invention provides pyrazolo[3,4-b]pyridine compounds of formula (I) having a —C(O)—NH—C(R 4 )(R 5 )-aryl substituent at the 5-position of the pyrazolo[3,4-b]pyridine ring system wherein at least one of R 4 and R 5 is not a hydrogen atom (H) compound or a salt thereof: wherein Ar has the sub-formula (x) or (z). These compounds are useful as inhibitors of PDE4.

  本发明提供了式(I)的吡唑并[3,4-b]吡啶化合物，其在吡唑并[3,4-b]吡啶环系的5位具有—C(O)—NH—C(R4)(R5)-芳基取代基，其中R4和R5中至少有一个不是氢原子（H）化合物或其盐：其中Ar具有亚式（x）或（z）。这些化合物可用作PDE4的抑制剂。
• PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS
  申请人：Allen David George

  公开号：US20080132536A1

  公开（公告）日：2008-06-05

  The invention provides a compound of formula (I) or a salt thereof: wherein Ar has the sub-formula (x) or (z): and wherein R 3 is optionally substituted C 3-8 cycloalkyl, optionally substituted C 5-7 cycloalkenyl, an optionally substituted heterocyclic group (aa), (bb) or (cc), or a bicyclic group (ee); and wherein R 4 is H, C 1-3 alkyl, C 1-2 fluoroalkyl, cyclopropyl, —CH 2 OR 4a , —CH(Me)OR 4a , or —CH 2 CH 2 OR 4a ; and R 5 is inter alia H, C 1-8 alkyl, C 1-3 fluoroalkyl, C 3-8 cycloalkyl, certain substituted alkyl groups, —(CH 2 ) n 13 -Het, or optionally substituted phenyl or —CH 2 -Ph; or R 4 and R 5 taken together are —(CH 2 ) p 1 — or —(CH 2 ) p 3 —X 5 —(CH 2 ) p 4 —; provided that at least one of R 4 and R 5 is not a hydrogen atom (H). The invention also provides the use of the compounds as inhibitors of phosphodiesterase type IV (PDE4) and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, allergic rhinitis or atopic dermatitis.

  该发明提供了式(I)的化合物或其盐： 其中Ar具有亚式(x)或(z)： 其中，R3是可选的取代C3-8环烷基，可选的取代C5-7环烯基，可选的取代的杂环基(aa)，(bb)或(cc)，或者是双环基(ee)； 其中，R4是氢，C1-3烷基，C1-2氟代烷基，环丙基，—CH2OR4a，—CH(Me)OR4a或—CH2CH2OR4a； 而R5则是包括氢、C1-8烷基、C1-3氟代烷基、C3-8环烷基、某些取代烷基、—(CH2)n13-Het，或可选取代的苯基或—CH2-Ph等的基团； 或者，R4和R5在一起是—(CH2)p1—或—(CH2)p3—X5—(CH2)p4—； 但是至少其中一个R4和R5不是氢原子（H）。 该发明还提供了将这些化合物用作磷酸二酯酶IV（PDE4）的抑制剂和/或用于治疗和/或预防炎症和/或过敏性疾病，如慢性阻塞性肺疾病（COPD）、哮喘、类风湿性关节炎、过敏性鼻炎或特应性皮炎的用途。
• Kinbara, Kazushi; Harada, Yoshiko; Saigo, Kazuhiko, Journal of the Chemical Society. Perkin Transactions 2 (2001), 2000, # 7, p. 1339 - 1347
  作者：Kinbara, Kazushi、Harada, Yoshiko、Saigo, Kazuhiko

  DOI：——

  日期：——
• Resolution of 1-arylalkylamines with 3-O-hydrogen phthalate glucofuranose derivatives: role of steric bulk in a family of resolving agents
  作者：Hari Babu Mereyala、Sreenivasulu Reddy Koduru、Venkata Narasimhaji Cheemalapati

  DOI：10.1016/j.tetasy.2006.01.005

  日期：2006.1

  The development of three new acidic resolving agents which are hydrogen plithalates of 1,2:5,6-di-O-isopropylidene-alpha-D-glucofuranose 1, 1,2:5,6-di-O-cyclohexylidene-alpha-D-glucofuranose 2 and 1,2-O-cyclohexylidene-5,6-O-diphenylmethylidene-alpha-D-glucofuranose 3 is shown for the resolution of 1-arylalkylamines 7a-k. The salts between 1, 2 and (RS)-1-arylalkylamines 7a-k selectively crystallize 1(.)(S) 7a j and 2(.)(S) 7a-h salts, allowing us to recover the corresponding bases (S) 7a-j and (S) 7a-h, respectively, in good yield and enantiomeric excess (73-95% ee). Whereas, the salts between 3 and (RS)-1-arylalkylamines 7a-c,g-i,k selectively crystallize 3-(S)-7a-c-g-i salts to recover the corresponding bases (S)-7a-c,g-i in poor enantionieric excess (4-35% ee). The difference between the resolving ability of 1 and 2 for 1-arylalkylamines 7a-h is very slight, but there is considerable difference compared to ortho-substituted 1-arylalkylamines 7i and 7j. The role of substituents on a family of resolving agents 1, 2 and 3 is also discussed to interpret their resolving ability. (c) 2006 Published by Elsevier Ltd.
• Resolution of 1-arylalkylamines with 6-(1,2:3,4-di-O-isopropylidene-α-d-galactopyranosyl)hydrogen phthalate
  作者：Hari Babu Mereyala、Liyakat Fatima、Pallavi Pola

  DOI：10.1016/j.tetasy.2003.12.038

  日期：2004.2

  The resolving ability of a new acidic resolving agent, the hydrogen phthalate of 1,2:3,4-di-O-isopropylidene-alpha-D-gal actopyranose 1, against various 1-arylalkylamines 2a-k is described. Treatment of 1 with amines 2a-f to obtain diastereomeric salts 1-(S)2a-f in 2-propanol allowing the corresponding (S)-amines 2a-f to be recovered in good yield and 61-89% ee. Recrystallization in dichloromethane/hexane, and regeneration gave the amines in enhanced enantiomeric purity (>98% ee). 1 resolved 1-phenylpropylamine 2f in high enantiomeric purity (99% ee) than 1-phenylethylamine 2g (11% ee) and o- and m-methoxy 2h-i, o-chloro-2j and p-fluoro-2k substituted 1-arylamines (11-19% ee). A possible chiral recognition mechanism based on the ability of I to exist in two conformations is described. (C) 2004 Published by Elsevier Ltd.